News on ThromboGenics NV from BioPortfolio.com http://www.BioPortfolio.com Consolidated ThromboGenics NV news from BioPortfolio.com Wed, 10 Feb 2010 15:27:41 GMT en Medical News: ThromboGenics Positive Microplasmin Phase II Data Published In Ophthalmologyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042115&HITNO=0&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042115&THISHREF=http://c.moreover.com/click/here.pl%3fz2539318740%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042115&HITNO=0&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042115&THISHREF=http://c.moreover.com/click/here.pl%3fz2539318740%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioFind: ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmologyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038827&HITNO=1&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038827&THISHREF=http://c.moreover.com/click/here.pl%3fz2537788825%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038827&HITNO=1&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038827&THISHREF=http://c.moreover.com/click/here.pl%3fz2537788825%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: ThromboGenics Positive Microplasmin Phase II Data Published In Ophthalmologyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4040860&HITNO=2&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4040860&THISHREF=http://c.moreover.com/click/here.pl%3fz2538907624%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4040860&HITNO=2&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4040860&THISHREF=http://c.moreover.com/click/here.pl%3fz2538907624%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedical News Today: ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmologyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035631&HITNO=3&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035631&THISHREF=http://c.moreover.com/click/here.pl%3fz2536307034%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035631&HITNO=3&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035631&THISHREF=http://c.moreover.com/click/here.pl%3fz2536307034%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmologyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034847&HITNO=4&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034847&THISHREF=http://c.moreover.com/click/here.pl%3fz2536011286%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034847&HITNO=4&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034847&THISHREF=http://c.moreover.com/click/here.pl%3fz2536011286%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Thrombogenics announces publication of positive microplasmin Phase II trial resultshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034338&HITNO=5&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034338&THISHREF=http://c.moreover.com/click/here.pl%3fz2535719961%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034338&HITNO=5&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034338&THISHREF=http://c.moreover.com/click/here.pl%3fz2535719961%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmologyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033569&HITNO=6&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033569&THISHREF=http://c.moreover.com/click/here.pl%3fz2535272486%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033569&HITNO=6&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033569&THISHREF=http://c.moreover.com/click/here.pl%3fz2535272486%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comRBC Dain Rauscher: Enrollment Completed for Phase 3 Trial of Nonsurgical Eye Disease Treatmenthttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032095&HITNO=7&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032095&THISHREF=http://c.moreover.com/click/here.pl%3fz2534500609%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032095&HITNO=7&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032095&THISHREF=http://c.moreover.com/click/here.pl%3fz2534500609%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comCataract & Refractive Surgery Today: BioInvent Plans to Raise $21M in Share Offering to Push Pipelinehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3911709&HITNO=8&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3911709&THISHREF=http://c.moreover.com/click/here.pl%3fz2469825082%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3911709&HITNO=8&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3911709&THISHREF=http://c.moreover.com/click/here.pl%3fz2469825082%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioWorld: BioInvent Plans to Raise $21M in Share Offering to Push Pipelinehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3910899&HITNO=9&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3910899&THISHREF=http://c.moreover.com/click/here.pl%3fz2469215322%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3910899&HITNO=9&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3910899&THISHREF=http://c.moreover.com/click/here.pl%3fz2469215322%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: ThromboGenics expects microplasmin trial results this yearhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3873525&HITNO=10&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3873525&THISHREF=http://c.moreover.com/click/here.pl%3fz2450048943%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3873525&HITNO=10&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3873525&THISHREF=http://c.moreover.com/click/here.pl%3fz2450048943%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comOphthalmology Times: ThromboGenics expects microplasmin trial results this yearhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3867538&HITNO=11&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3867538&THISHREF=http://c.moreover.com/click/here.pl%3fz2447205242%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3867538&HITNO=11&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3867538&THISHREF=http://c.moreover.com/click/here.pl%3fz2447205242%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comModern Medicine: ThromboGenics expects microplasmin trial results later this yearhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3863013&HITNO=12&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3863013&THISHREF=http://c.moreover.com/click/here.pl%3fz2445319435%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3863013&HITNO=12&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3863013&THISHREF=http://c.moreover.com/click/here.pl%3fz2445319435%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comModern Medicine: First Patient Treated in BioInvent's Phase I Study of the Drug Ca...http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3850712&HITNO=13&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3850712&THISHREF=http://c.moreover.com/click/here.pl%3fz2439970393%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3850712&HITNO=13&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3850712&THISHREF=http://c.moreover.com/click/here.pl%3fz2439970393%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comZibb: BioInvent and ThromboGenics Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3643893&HITNO=14&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3643893&THISHREF=http://c.moreover.com/click/here.pl%3fz2338020774%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3643893&HITNO=14&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ThromboGenics%20NV&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3643893&THISHREF=http://c.moreover.com/click/here.pl%3fz2338020774%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: